Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,065 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.
Matsue Y, Ter Maaten JM, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, van der Meer P, Damman K, Voors AA, Goldsmith SR. Matsue Y, et al. Among authors: onishi y. Clin Res Cardiol. 2017 Oct;106(10):802-812. doi: 10.1007/s00392-017-1122-1. Epub 2017 May 24. Clin Res Cardiol. 2017. PMID: 28540483 Free PMC article. Clinical Trial.
Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.
Matsue Y, Suzuki M, Nagahori W, Yoshida K, Onishi Y, Satoh Y, Ono Y, Nishioka T, Noda M, Sugi K, Torii S, Tejima T, Sakurada H, Yamaguchi S, Okishige K, Fujii H, Takahashi A. Matsue Y, et al. Among authors: onishi y. Cardiovasc Drugs Ther. 2014 Feb;28(1):73-7. doi: 10.1007/s10557-013-6491-8. Cardiovasc Drugs Ther. 2014. PMID: 24048511 Clinical Trial.
Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction.
Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR. Matsue Y, et al. Among authors: onishi y. J Card Fail. 2016 Jun;22(6):423-32. doi: 10.1016/j.cardfail.2016.02.007. Epub 2016 Feb 23. J Card Fail. 2016. PMID: 26915749 Clinical Trial.
Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction.
Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR. Matsue Y, et al. Among authors: onishi y. Int J Cardiol. 2016 Oct 15;221:188-93. doi: 10.1016/j.ijcard.2016.07.063. Epub 2016 Jul 5. Int J Cardiol. 2016. PMID: 27404673 Clinical Trial.
Corrigendum to "Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction" Journal of Cardiac Failure, Vol. 22, No. 6, June 2016, pp. 423-432.
Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR. Matsue Y, et al. Among authors: onishi y. J Card Fail. 2016 Nov;22(11):941. doi: 10.1016/j.cardfail.2016.07.434. Epub 2016 Jul 29. J Card Fail. 2016. PMID: 27481596 No abstract available.
Prognostic importance of sodium level trajectory in acute heart failure.
Matsue Y, Yoshioka K, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, Goldsmith SR. Matsue Y, et al. Among authors: onishi y. Heart Vessels. 2017 Dec;32(12):1498-1505. doi: 10.1007/s00380-017-1020-5. Epub 2017 Jul 11. Heart Vessels. 2017. PMID: 28698994 Clinical Trial.
Comparison of arterial remodeling and changes in plaque composition between patients with progression versus regression of coronary atherosclerosis during statin therapy (from the TRUTH study).
Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Sato A, Nozato T, Miyake S, Takeyama Y, Morino Y, Yamauchi T, Muramatsu T, Hibi K, Terashima M, Michishita I; TRUTH Investigators. Nozue T, et al. Among authors: onishi y. Am J Cardiol. 2012 May 1;109(9):1247-53. doi: 10.1016/j.amjcard.2011.12.016. Epub 2012 Feb 9. Am J Cardiol. 2012. PMID: 22325089 Clinical Trial.
Comparison of effects of serum n-3 to n-6 polyunsaturated fatty acid ratios on coronary atherosclerosis in patients treated with pitavastatin or pravastatin undergoing percutaneous coronary intervention.
Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Sato A, Nozato T, Miyake S, Takeyama Y, Morino Y, Yamauchi T, Muramatsu T, Hibi K, Terashima M, Michishita I. Nozue T, et al. Among authors: onishi y. Am J Cardiol. 2013 Jun 1;111(11):1570-5. doi: 10.1016/j.amjcard.2013.01.327. Epub 2013 Mar 13. Am J Cardiol. 2013. PMID: 23497779 Clinical Trial.
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators. McMurray JJV, et al. N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19. N Engl J Med. 2019. PMID: 31535829 Clinical Trial.
1,065 results